Gara Jalqabaatti › Saree Oljoo › Missouri › St. Louis
Qorannoo klinikaalii Saree Oljoo St. Louis, MO keessatti
Qorannoo 64 Saree Oljoo f St. Louis fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
The Vanguard Study: Testing a New Way to Screen for Cancer
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Washington University School of Medicine, St Louis
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Washington University School of Medicine- Siteman Cancer Center, St Louis
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Mercy Infusion Center - Chippewa, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- fi 4 dabalataa
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- Washington University, School of Medicine, St Louis
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Washington University School of Medicine, St Louis
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Washington University School of Medicine, St Louis
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Washington University in St Louis, St Louis
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Namoota walitti qabaa jiraSadarkaa 3
- Washington University School of Medicine ( Site 0076), St Louis
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, St Louis
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Washington University School of Medicine- Siteman Cancer Center, St Louis
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Namoota walitti qabaa jiraSadarkaa 3
- Washington University Siteman Cancer Center ( Site 0031), St Louis
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Local Institution - 0140, St Louis
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Namoota walitti qabaa jira
- Mercy Health - Sindelar Cancer Center, St Louis
- Mercy Health - Pratt Cancer Center, St Louis
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Namoota walitti qabaa jiraSadarkaa 1
- Washington University, St Louis
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Washington University School of Medicine in St. Louis, St Louis
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Washington University School of Medicine, St Louis
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Washington University School of Medicine, St Louis
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Cancer Care Specialists of Illinois, O'Fallon · Miili 16 fagaatti
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Namoota walitti qabaa jiraSadarkaa 1/2
- Washington Univ. School of Medicine, St Louis
Precision Supplemental Imaging in Women With Dense Breasts
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Washington University School of Medicine, St Louis
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Namoota walitti qabaa jiraSadarkaa 3
- Siteman Cancer Center, St Louis
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, St Louis
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Washington University School of Medicine, St Louis
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Washington University School of Medicine, St Louis
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Washington University Medical School, St Louis
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Washington University Siteman Cancer Center, St Louis
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Cancer Care Specialists of Central Illinois, O'Fallon · Miili 16 fagaatti
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Namoota walitti qabaa jiraQorannoo ilaalaa
- Cancer Care Specialist of Illinois, O'Fallon · Miili 16 fagaatti
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Namoota walitti qabaa jiraQorannoo ilaalaa
- Washington University School of Medicine, St Louis
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Namoota walitti qabaa jiraSadarkaa 3
- Mercy Infusion Center - Chippewa, St Louis
- Washington University School of Medicine, St Louis
- Mercy Hospital South, St Louis
- fi 9 dabalataa
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Washington University, St Louis
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- WA Uni School Of Med, St Louis
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Washington University School of Medicine - Siteman Cancer Center, St Louis
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Washington University, Siteman Cancer Center, St Louis
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Namoota walitti qabaa jiraSadarkaa 3
- Washington University School of Medicine, St Louis
- Mercy Hospital South, St Louis
- Siteman Cancer Center-South County, St Louis
- fi 4 dabalataa
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Washington University School of Medicine, St Louis
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Namoota walitti qabaa jiraSadarkaa 3
- Siteman Cancer Center - Washington University Medical Campus, St Louis
IDOV-Immune for Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Washington University School of Medicine, St Louis
E-Mindfulness Approaches for Living After Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- Cancer Care Center of O'Fallon, O'Fallon · Miili 16 fagaatti
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Namoota walitti qabaa jiraSadarkaa 2
- Washington University School of Medicine, St Louis
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Namoota walitti qabaa jiraSadarkaa 2
- Washington University School of Medicine, St Louis
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Investigative Site #110, St Louis
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Washington University School of Medicine, St Louis
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Washington University, St Louis
Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
Namoota walitti qabaa jira
- Washington University School of Medicine, St Louis
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Namoota walitti qabaa jiraSadarkaa 3
- Washington University School of Medicine, St Louis
ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction
Namoota walitti qabaa jira
- Washington University School of Medicine, St Louis
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Namoota walitti qabaa jiraSadarkaa 3
- Washington University School of Medicine in Saint Louis, St Louis
COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients
Namoota walitti qabaa jiraQorannoo ilaalaa
- Washington University School of Medicine, St Louis
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Namoota walitti qabaa jiraSadarkaa 3
- Siteman Cancer Center, St Louis
- Siteman Cancer Center - North County, Florissant · Miili 13 fagaatti
- Memorial Hospital., Shiloh · Miili 17 fagaatti
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Namoota walitti qabaa jiraSadarkaa 3
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- Mercy Hospital Saint Louis, St Louis
- fi 3 dabalataa
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Namoota walitti qabaa jiraSadarkaa 1/2
- Washington University School of Medicine, St Louis
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Washington University School of Medicine, St Louis
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Namoota walitti qabaa jiraQorannoo ilaalaa
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- Mercy Hospital Saint Louis, St Louis
- fi 4 dabalataa
Cryoablation vs Lumpectomy in T1 Breast Cancers
Namoota walitti qabaa jira
- Washington University School of Medicine, St Louis
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Washington University School of Medicine, St Louis
Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Washington University School of Medicine, St Louis
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
Namoota walitti qabaa jira
- Washington University School of Medicine, St Louis
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
Namoota walitti qabaa jiraQorannoo ilaalaa
- Washington University School of Medicine, St Louis
WashU DIEP Flap Video and Patient Understanding Improvement
Namoota walitti qabaa jira
- Washington University School of Medicine, St Louis
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, St Louis
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Namoota walitti qabaa jiraSadarkaa 3
- Saint Louis Cancer and Breast Institute-South City, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- fi 2 dabalataa
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Washington University School of Medicine St. Louis, St Louis
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Namoota walitti qabaa jiraQorannoo ilaalaa
- Washington University School of Medicine, St Louis
Qorannoo Saree Oljoo magaalota biroo keessatti
- New York City, NYQorannoo 136
- Houston, TXQorannoo 126
- Boston, MAQorannoo 112
- Nashville, TNQorannoo 81
- Los Angeles, CAQorannoo 73
- Edison, NJQorannoo 68
- Queens, NYQorannoo 64
- Durham, NCQorannoo 64
- Chicago, ILQorannoo 59
- Philadelphia, PAQorannoo 56
- Dallas, TXQorannoo 55
- Arlington, VAQorannoo 47
Qorannoo biroo St. Louis keessatti
- Kansara Qara'a Non-Small CellQorannoo 73
- Kansara MetastatikiiQorannoo 54
- Kansarii ColorectalQorannoo 50
- Saree (Gosoota Hunda)Qorannoo 46
- Kansarii ProstateQorannoo 46
- Dhibee QaraQorannoo 39
- Kansarii OvariiQorannoo 38
- Kansarii PancreasQorannoo 33
- Kansa EndometiriyaaliiQorannoo 29
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 28
- Cufama OnneeQorannoo 26
- ObesityQorannoo 25
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.